STOCK TITAN
  1. Home
  2. News
  3. INKT

MiNK Therapeutics, Inc. - INKT STOCK NEWS

Welcome to our dedicated page for MiNK Therapeutics news (Ticker: INKT), a resource for investors and traders seeking the latest updates and insights on MiNK Therapeutics stock.

MiNK Therapeutics, Inc. (NASDAQ: INKT) is a clinical-stage biopharmaceutical company dedicated to developing cutting-edge therapies for treating cancer and other immune-mediated diseases. The company's core focus lies in pioneering allogeneic invariant natural killer T (iNKT) cell therapies, which are designed to be off-the-shelf solutions, making them readily available for patients in need.

MiNK's flagship program, agenT-797, is currently in a Phase 2 trial aimed at treating second-line gastroesophageal cancer. This trial, led by Dr. Yelena Janjigian at Memorial Sloan Kettering Cancer Center, builds on promising results from earlier studies where agenT-797 demonstrated the ability to overcome resistance to immune checkpoint inhibitors. The trial is exploring the combination of agenT-797 with other advanced treatments, such as botensilimab and balstilimab, to improve outcomes for patients with challenging gastrointestinal cancers.

Another significant candidate in MiNK's pipeline is MiNK-215, an IL-15 armored FAP-targeting CAR iNKT cell therapy. This candidate has shown remarkable efficacy in preclinical models for colorectal cancer liver metastases, overcoming the immune barriers typically posed by liver metastases.

The company recently reported a strong year-end financial position with ongoing collaborations, including a research agreement with ImmunoScape. MiNK Therapeutics continues to advance its clinical programs while maintaining a focus on scalable and reproducible manufacturing processes for its iNKT cell therapies.

Founded and headquartered in New York, NY, MiNK Therapeutics remains committed to delivering innovative and effective treatments for life-threatening diseases. For more information, visit their website or follow them on social media at @MiNK_iNKT.

News

MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications

Rhea-AI Summary
MiNK Therapeutics, Inc. (NASDAQ: INKT) announced promising results from a phase 1/2 study of agenT-797 in patients with severe respiratory distress due to SARS-CoV-2. The study showed improved survival rates, with over 70% survival in patients on mechanical ventilation and an 80% survival rate in patients on VV ECMO. AgenT-797 also demonstrated the ability to induce anti-inflammatory biomarkers, prevent secondary infections, and reduce pneumonia by over 80%. The results highlight the potential of allogeneic iNKT cell therapies in treating severe respiratory distress and immune-related diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.2%
Tags
none
-
News

MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

Rhea-AI Summary
MiNK Therapeutics, Inc. (NASDAQ: INKT) announced a case report highlighting the potential of iNKT cell therapies to treat advanced solid tumors. The study showed a durable confirmed partial response in a patient with gastric cancer refractory to anti-PD1, indicating the unique potential of iNKT cells to overcome resistance to immune checkpoint inhibitors. The company is continuing to advance iNKT cells in this setting and is looking forward to further updates on its solid tumor programs this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
none
-
News

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

Rhea-AI Summary
MiNK Therapeutics, Inc (Nasdaq: INKT) and ImmunoScape collaborate to develop TCR-based therapies for solid tumors, leveraging MiNK's proprietary library of T-cell antigens and ImmunoScape's Deep Immunomics platform. The collaboration aims to accelerate the development of next-generation TCR therapies against novel targets in solid tumors, offering new therapeutic approaches for diverse cancer indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

MiNK Therapeutics Reports Third Quarter 2023 Results

Rhea-AI Summary
MiNK Therapeutics, Inc. (NASDAQ: INKT) reports positive financial results for Q3 2023, highlights data showing durable clinical benefit in solid tumor cancers and potential in severe respiratory distress. AgenT-797 demonstrates improved survival in late-stage metastatic cancer patients. The company plans to expand into autoimmune and inflammatory diseases. A conference call is scheduled for November 9, 2023, at 8:30 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.72%
Tags
earnings
-
News

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Rhea-AI Summary
MiNK Therapeutics, Inc. presented new data on their allogeneic cell therapy, agenT-797, at the Society for Immunotherapy of Cancer's Annual Meeting. The therapy showed clinical benefit in heavily pre-treated patients with solid tumors, including long-term disease stabilization and tolerable safety profile. AgenT-797 demonstrated long-term persistence and induced a potent anti-tumor response. Expansion of clinical programs is underway in additional solid tumor settings, and a randomized phase 2 trial in gastric cancer is expected to launch by year-end 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.59%
Tags
none
-
News

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

Rhea-AI Summary
MiNK Therapeutics, Inc. (NASDAQ: INKT) will release its third quarter 2023 financial results on Nov. 9, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.57%
Tags
earnings
News

MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Rhea-AI Summary
MiNK Therapeutics (NASDAQ: INKT) plans to unveil updated clinical and translational data on agenT-797's mechanism of action in solid tumors at the SITC Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
conferences
-
News

MiNK Therapeutics to Participate in September Investor Conferences

Rhea-AI Summary
MiNK Therapeutics (Nasdaq: INKT) announces CEO participation in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.24%
Tags
conferences
-
News

MiNK Therapeutics Reports Second Quarter 2023 Results

Rhea-AI Summary
MiNK Therapeutics, Inc. (INKT) reported significant clinical progress with agenT-797, an allogeneic iNKT therapy, showing persistence and clinical benefit in patients with solid tumor cancers. The company announced a planned launch of a randomized Phase 2 trial in 2L gastric cancer, as well as progress on a novel FAP-CAR-iNKT cell therapy, MiNK-215, that eliminated tumors in NSCLC models. Financial results indicated a cash balance of $10.6 million at the end of the second quarter 2023, with a net loss of $11.9 million for the first six months of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
earnings
News

MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.59%
Tags
earnings

FAQ

What is the current stock price of MiNK Therapeutics (INKT)?

The current stock price of MiNK Therapeutics (INKT) is $1.01 as of January 22, 2025.

What is the market cap of MiNK Therapeutics (INKT)?

The market cap of MiNK Therapeutics (INKT) is approximately 34.9M.

What does MiNK Therapeutics specialize in?

MiNK Therapeutics specializes in developing allogeneic invariant natural killer T (iNKT) cell therapies for treating cancer and immune-mediated diseases.

What is agenT-797?

AgenT-797 is MiNK Therapeutics' leading iNKT cell therapy currently in Phase 2 trials for treating second-line gastroesophageal cancer.

What are the recent achievements of MiNK Therapeutics?

Recent achievements include dosing the first patient in a Phase 2 trial for agenT-797 and presenting promising preclinical data for MiNK-215 in treating colorectal cancer liver metastases.

Where is MiNK Therapeutics headquartered?

MiNK Therapeutics is headquartered in New York, NY.

What partnerships has MiNK Therapeutics established?

MiNK Therapeutics has key partnerships, including a research agreement with ImmunoScape and collaboration with Agenus for drug combinations.

What is MiNK-215?

MiNK-215 is an IL-15 armored FAP-targeting CAR iNKT cell therapy developed by MiNK Therapeutics for treating colorectal cancer liver metastases.

How does MiNK Therapeutics deliver their therapies?

MiNK Therapeutics focuses on scalable and reproducible manufacturing processes for off-the-shelf delivery of their iNKT cell therapies.

How can investors get more information about MiNK Therapeutics?

Investors can visit the company's website or reach out via their investor email at investor@minktherapeutics.com.

What is the primary focus of MiNK Therapeutics' current research?

The primary focus is on advancing iNKT cell therapies like agenT-797 and MiNK-215 in clinical trials for various cancer types.

How does agenT-797 work?

AgenT-797 works by targeting cancerous cells and enhancing the immune response, particularly when used in combination with other immune checkpoint inhibitors.
Stock INKT logo
MiNK Therapeutics, Inc.

Nasdaq:INKT

INKT Rankings

#5111 Ranked by Market Cap
N/A Ranked by Dividends

INKT Stock Data

34.91M
10.07M
74.65%
2.25%
0.13%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
NEW YORK